Phase 3 Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with glaucoma in the eye being studied, AND it is not controlled even when using the maximum number of eye pressure-lowering medications (four or more types, or fewer if some medications cannot be used due to side effects or other reasons), AND at least one eye surgery for glaucoma (such as a filtering surgery or tube implant) has already been tried without success.
- You have glaucoma in the eye being studied that is not controlled by medications alone (even without prior surgery) — note that only a limited number of participants (up to 10 per group) can join under this condition.
Who may not be able to join:
- You have a type of glaucoma called angle-closure glaucoma in the eye being studied, and the angle has not been surgically opened.
- You have a type of glaucoma in the eye being studied that was caused by another condition, such as abnormal blood vessel growth, pigment, inflammation, injury, or other secondary causes.
- You currently have active inflammation or infection in the eye being studied, such as eyelid irritation, pink eye, corneal infection, or internal eye inflammation.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants With Treatment Response of Achieving ≥ 20% Reduction in Intraocular Pressure (IOP) From Baseline on the Same or Fewer Number of IOP-Lowering Medications Compared to Baseline; Number of Participants with Adverse Events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.